GlucoWatch Recommendation Conditioned On Extensive Education Program
This article was originally published in The Gray Sheet
Executive Summary
Cygnus, Inc. should develop an "extensive education program" for both physicians and patients in the use of the firm's GlucoWatch Biographer wrist-worn semi-continuous glucose meter, members of FDA's Clinical Chemistry and Clinical Toxicology Devices Panel agreed Dec. 6 in Gaithersburg, Maryland.
You may also be interested in...
Cygnus GlucoWatch Pilot Marketing Program To Begin In April
Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.
Cygnus GlucoWatch Pilot Marketing Program To Begin In April
Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.
Cygnus Sizzles In June; Stock Rises 77% On Heels Of Diabetes Conference
The stock prices of diabetes product manufacturers Cygnus and MiniMed headed in opposite directions in the aftermath of the June 9-13 annual meeting of the American Diabetes Association.